albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-08. Numbers and descriptions here follow the published literature rather than marketing material.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
The process of RNAi was referred to as "co-suppression" and "quelling" when observed prior to the knowledge of an RNA-related mechanism. The discovery of RNAi was preceded first by observations of transcriptional inhibition by antisense RNA expressed in transgenic plants, and more directly by reports of unexpected outcomes in experiments performed by plant scientists in the United States and the Netherlands in the early 1990s. In an attempt to alter flower colors in petunias, researchers introduced additional copies of a gene encoding chalcone synthase, a key enzyme for flower pigmentation into petunia plants of normally pink or violet flower color. The overexpressed gene was expected to result in darker flowers, but instead caused some flowers to have less visible purple pigment, sometimes in variegated patterns, indicating that the activity of chalcone synthase had been substantially decreased or became suppressed in a context-specific manner. Another early observation of RNAi came from a study of the fungus Neurospora crassa, although it was not immediately recognized as related. Further investigation of the phenomenon in plants indicated that the downregulation was due to post-transcriptional inhibition of gene expression via an increased rate of mRNA degradation. This phenomenon was called co-suppression of gene expression, but the molecular mechanism remained unknown. Not long after, plant virologists working on improving plant resistance to viral diseases observed a similar unexpected phenomenon.
Stained brain slice images which include the "Hypothalamus" at the BrainMaps project The Hypothalamus and Pituitary at endotexts.org NIF Search - Hypothalamus via the Neuroscience Information Framework Space-filling and cross-sectional diagrams of hypothalamic nuclei: right hypothalamus, anterior, tubular, posterior.
The ratio of the velocity of a species of particle to the average velocity of the fluid is called the retention ratio R. In FFF for efficient separation, R needs to be below 0.2, typical values are in the range of 0.02 to 0.1.
== Contraindications == Anyone who is unstable for surgery should not undergo flap surgery. As with most surgeries, people who are sicker may have more difficulties with wound healing. Comorbidities include diabetes, smoking, immunosuppression, and vascular disease.
== Research directions == Research is being done to identify the proteins cleaved by calpain-3. Gene therapy is being studied to replace the function of the calpain-3. Injection of plasmids containing CAPN3 into mouse models resulted in increased levels of calpain-3.
Sources: en.wikipedia.org
=== Biological activity === 90Sr is a "bone seeker" that exhibits biochemical behavior similar to calcium, the next lighter group 2 element. After entering the organism, most often by ingestion with contaminated food or water, about 70–80% of the dose gets excreted. Virtually all remaining 90Sr is deposited in bones and bone marrow, with the remaining 1% remaining in blood and soft tissues. Its presence in bones can cause bone cancer, cancer of nearby tissues, and leukemia. Exposure to 90Sr can be tested by a bioassay, most commonly by urinalysis. The biological half-life of 90Sr in humans has variously been reported as 14 to 600 days, 1,000 days, 18 years, 30 years and, at the upper limit, 49 years. The wide-ranging published biological half-life figures are explained by strontium's complex metabolism within the body. However, by averaging all excretion paths, the overall biological half-life is estimated to be about 18 years. The elimination rate of 90Sr is strongly affected by age and sex, due to differences in bone metabolism. Together with cesium-134 (134Cs), 137Cs and iodine-131 (131I), 90Sr was among the most important isotopes regarding health impacts after the Chernobyl disaster. As strontium has an affinity to the calcium-sensing receptor of parathyroid cells that is similar to that of calcium, the increased risk of liquidators of the Chernobyl power plant to suffer from primary hyperparathyroidism could be explained by binding of 90Sr.
==== Cell-based platform ==== The immune system plays an important role in cancer and can be harnessed to attack cancer cells. Cell-based therapies focus on immunotherapies, mostly by engineering T cells. T cell receptors were engineered and 'trained' to detect cancer epitopes. Chimeric antigen receptors (CARs) are composed of a fragment of an antibody fused to intracellular T cell signaling domains that can activate and trigger proliferation of the cell. Multiple second generation CAR-based therapies have been approved by FDA. Gene switches were designed to enhance safety of the treatment. Kill switches were developed to terminate the therapy should the patient show severe side effects. Mechanisms can more finely control the system and stop and reactivate it. Since the number of T-cells are important for therapy persistence and severity, growth of T-cells is also controlled to dial the effectiveness and safety of therapeutics. Although several mechanisms can improve safety and control, limitations include the difficulty of inducing large DNA circuits into the cells and risks associated with introducing foreign components, especially proteins, into cells.
An extension of the WAG algorithm is used, with a new PhyML (WAG+Γ4) model taking into account of sites with different evolutionary rates. Qmaker and nQmaker (2021, 2022), programs with the ability to estimate time-reversible and nonreversible matrices from very large datasets quickly. Each provide a general matrix and 5 specialized matrices, for a total of 12 precalculated substitution matrices. Matrices using a selection of proteins based on structural relatedness, as proposed by Benner et al. (1994), Fan (2004), and Steven et al. (2004). Matrices using structural alignments of proteins instead of simple sequence alignment (6 separate publications). Matrices using known physiochemical parameters of amino acid residues (5 separate publications). For a list of more models (including irreversible i.e. asymmetric and/or specialized ones), see the documentation for recent bioinformatic software including IQ-Tree, PhyML, and RAxML.
Listed below are the athletes who have achieved a 1,000 pounds (453.6 kilograms) or more deadlift, a feat which has been accomplished by only 40 men in history. It includes both strongman and powerlifting deadlifts performed using only the conventional stance. Sanctioned lifts during competitions and exhibitions, as well as unsanctioned lifts during training (with video proof) are included.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.